Dry Eye Products Market Expected to Generate $4.5 Billion by 2020

January 22, 2016: By Katie Cannady

Market Scope expects sales of dry eye medications and devices at the manufacturer level to reach nearly $3.2 billion in 2015 and grow at a compounded annual growth rate of 6.9 percent over the next five years.

Factors contributing to growth include longer life expectancies and extended careers; an expanding middle class in emerging markets with increased access to health care; increased visual demands related to small phones, tablets, and computers; improved diagnostic technologies; and treatment regimens with enhanced effectiveness.

Market Scope estimates that nearly 337 million people suffer from severe, moderate, or episodic dry eye syndrome worldwide. Dry eye disease is a ubiquitous, complex, and multifactorial condition, and its effect on dry eye patients ranges from intermittent and annoying discomfort to a serious and chronic vision-threatening disorder. Given the pervasiveness of the condition, demand for dry eye treatments continues to increase worldwide and is spurred by a number of factors. Market Scope has identified 10 of the more common dry eye contributors and has estimated comorbidity among these various factors to assess dry eye populations and the market for dry eye treatments. Our analysis includes estimates for postmenopausal women, Sjögren’s syndrome patients, people with blepharitis/meibomian gland dysfunction, men over age 65, contact lens wearers, people with chronic ocular allergies, those suffering side effects from systemic drugs, those undergoing LASIK, those with previous LASIK, and others with dry eye in the general population.

Looking forward, we anticipate several changes in this dynamic market. Market Scope predicts growth in procedure-based treatment for meibomian gland dysfunction to continue as a new pricing model heralds further increases. An investigational procedure that stimulates tear production also holds significant promise and may enter the market in the next several years, expanding procedure-based options for dry eye treatment. During 2015, Europe saw its first dry eye Rx drug approval followed by a positive reimbursement decision in the UK’s key National Health Service, and we expect more European countries to follow suit. New dry eye Rx pharmaceuticals are also likely to enter markets by 2020, including the US market, where no new dry eye drug has gained regulatory approval since 2002.

The global dry eye market is dominated by three companies that collectively account for nearly 82 percent of total revenues: Novartis/Alcon, Allergan, and Santen.

Market Scope published its 2015 Comprehensive Report on the Global Dry Eye Products Market in December 2015. It remains the only source for accurate and relevant information on all aspects of the market. The report’s chapters cover dry eye syndrome’s etiology, diagnosis, and treatment. The report includes forecasts for dry eye’s prevalence around the world; product descriptions for Rx therapeutics, over-the-counter lubricants, punctum plugs, and additional dry eye procedures and products; forecasts for these dry eye product markets; and a review of the dry eye development pipeline. The report also includes profiles of companies marketing and developing dry eye products. This report includes market data for 2014, and we forecast market performance through 2020. Our forecast also subdivides the cataract equipment market into eight geographic/economic analytic categories: the US, Western Europe, Japan, Other Wealthy Nations, China, India, Latin America, and Rest of World.

Coming soon

2017 Ophthalmic Laser Report: A Global Market Analysis for 2016 to 2022 (Photocoagulation, Photodisruption, and SLT)